Assessment Of Clinical Efficacy Of Etanercept In The Treatment Of Non-Radiographicaxial Spondyloarthritis

Objective:The aim of this research was to describe the effectiveness of Etanercept in the treatment of non-radiographic axial spondyloarthritis(nr-axSpA). Methods:The data were collected online from the clinical registry of Second Affiliated Hospital of Nanchang University, which is one of Chinese Rheumatism Data Centers. Thirty five patients with active nr-axSpA were assigned Etanercept group, which receiving etanercept 50 mg subcutaneous injection once weekly and nonsteroidal antiinflammatory drugs(NSAIDs),or control group, which receiving only NSAIDs for 12 weeks. The primary end point was the proportion of patients who achieved the Assessment of SpondyloArthritis international Societycriteria for 20% improvement(ASAS20) and for 40% improvement(ASAS40) at 12 weeks. Other outcome measures included levels of erythrocyte sedimentation rate, levels of C-reactive protein, back pain, patient’s global assessment of disease activity, Bath Ankylosing Spondylitis Disease Activity Index(BASDAI), Bath Ankylosing Spondylitis Functional Index(BASFI) and Bath Ankylosing Spondylitis Metrology Index(BASMI). Results:At week 12, eigthteen patients(81.8%) in the etanercept group and four patients(30.8%) in the control group achieved ASAS20.Thirteen patients(59.1%) in the etanercept group and two patients(15.4%) in the control group achieved ASAS40. Significant improvement(P<0.01) was seen in measures of disease activity, CRP, ESR, back pain, patient’s global assessment of disease activity,morning stiffness, BASFI and BASDAI in etanercept group. But there was no obvious difference in the modified Schober’s test, cervical rotationchest expansion and BASMI. Improvement in CRP, back pain and morning stiffness was significantly in control group. While,at week 12, etanercept group did not give better results than control group for CRP, back pain and morning stiffness. Conclusion:The clinical efficacy of etanercept for the treatment of nr-axSpA is significant better than NSAIDs monotherapy.